background
bronchiol
due
adenoviru
nosocomi
infect
result
closur
pediatr
depart
northern
portug
object
determin
etiolog
bronchiol
northern
portug
studi
design
prospect
multicent
studi
etiolog
bronchiol
respiratori
syncyti
viru
rsv
season
novemberapril
children
month
age
admit
first
wheez
episod
includ
nasopharyng
specimen
analyz
indirect
immunofluorescentantibodi
assay
ifa
rsv
adenoviru
hadv
parainfluenza
piv
influenza
iv
b
polymeras
chain
reaction
pcr
revers
transcriptionpcr
virus
human
metapneumoviru
hmpv
bocaviru
hbov
rhinoviru
hrv
coronavirus
enteroviru
result
period
children
includ
ifa
analys
pcr
perform
ifa
detect
rsv
pcr
increas
ifa
detect
hadv
pcr
pcr
detect
iv
iv
b
piv
piv
piv
case
hbov
singl
agent
case
hrv
posit
sampl
hmpv
viru
panel
remain
without
etiolog
conclus
frequent
agent
rsv
follow
hadv
pcr
costeffect
accur
ifa
crucial
hadv
may
associ
signific
mortal
ifa
alon
detect
case
bronchiol
viral
lower
respiratori
tract
infect
vri
child
month
age
signssymptom
rhiniti
tachypnea
wheez
cough
crackl
use
accessori
muscl
andor
nasal
flare
american
academi
pediatr
aap
guidelin
recommend
diagnosi
base
histori
physic
examin
discourag
virolog
test
rare
impact
manag
state
use
patient
cohort
possibl
investig
determin
rel
viral
frequenc
children
bronchiol
conduct
prospect
multicent
studi
temper
northwest
region
portug
bound
north
galiza
west
atlant
ocean
studi
involv
hospit
region
children
month
admit
bronchiol
includ
aap
definit
adopt
hospit
histori
previou
wheez
episod
exclud
child
studi
start
first
respiratori
syncyti
viru
rsv
detect
conduct
novemb
parent
sign
written
inform
consent
fill
questionnair
child
nasopharyng
aspir
na
collect
patient
contribut
one
sampl
singl
child
multipl
sampl
earliest
select
rapid
viral
test
conduct
origin
hospit
use
indirect
immunofluorescentantibodi
assay
ifa
rsv
adenoviru
parainfluenza
virus
piv
influenza
viru
iv
b
hospit
follow
common
reagent
protocol
remain
sampl
frozen
c
transport
braga
hospit
bh
nucleic
acid
extract
perform
ml
sampl
use
magna
pure
total
nucleic
acid
isol
kit
roch
appli
scienc
extern
lysi
protocol
follow
manufactur
instruct
fmi
eluat
subject
seeplex
ase
seegen
usa
multiplex
realtim
pcr
rtpcr
detect
rsv
b
adenoviru
piv
type
iv
b
bocaviru
rhinoviru
coronoviru
enteroviru
perform
without
prior
knowledg
ifa
result
human
metapneumoviru
hmpv
analyz
rtpcr
ifa
pcr
gave
discrep
result
latter
confirm
rtpcr
rsv
pcr
bocaviru
nestedpcr
adenoviru
use
primer
probe
condit
describ
literatur
studi
approv
bh
ethic
committe
period
children
hospit
bronchiol
na
analyz
ifa
pcr
loss
due
collect
insuffici
materi
error
freez
transport
n
rsv
detect
ifa
case
falseposit
falseneg
identifi
pcr
n
rate
detect
increas
pcr
rsv
respons
rsv
b
adenoviru
detect
case
ifa
alon
pcr
falseposit
falseneg
detect
rate
rais
n
ifa
alon
detect
case
iv
none
iv
b
pcr
detect
iv
iv
b
falseneg
falseposit
n
total
posit
iv
case
iv
b
case
piv
detect
sampl
ifa
test
pcr
n
piv
present
sampl
ifa
pcr
falseposit
falseneg
n
detect
increas
case
piv
detect
sampl
ifa
alon
falseposit
falseneg
n
number
case
declin
found
case
posit
bocaviru
singl
agent
case
n
rhinoviru
n
hmpv
n
sampl
analyz
coronaviru
enteroviru
neg
n
posit
case
ifa
neg
pcr
doubl
check
rtpcr
remain
neg
fig
describ
rel
frequenc
viru
infect
caus
one
viru
present
evalu
extens
panel
virus
case
remain
without
etiolog
demonstr
use
sensit
molecularbas
assay
high
rate
respiratori
viru
detect
among
larg
sampl
children
evalu
bronchiol
hospit
set
rsv
frequent
agent
detect
two
third
children
previou
studi
analys
viral
detect
capac
cultur
ifa
multiplex
pcr
children
vri
found
pcr
sensit
method
children
viru
detect
na
anoth
studi
infant
lower
vri
perform
pcr
na
detect
virus
patient
valu
quit
similar
major
studi
report
rsv
common
agent
preval
rhinoviru
much
higher
studi
mainli
design
ambulatori
care
probabl
mainli
caus
upper
airway
diseas
need
admiss
found
high
rate
falseneg
use
ifa
alon
mainli
adenoviru
pcr
tripl
rate
detect
import
sinc
adenoviru
associ
signific
morbid
mortal
sequenc
variat
primerprob
sequenc
uncommon
viru
may
result
fals
neg
pcr
second
pcr
assay
direct
anoth
part
genom
use
rtpcr
necessari
piv
rate
detect
decreas
use
pcr
want
emphas
presenc
bocaviru
caus
agent
detect
case
singl
agent
one
child
diarrhoea
associ
may
suggest
bocaviru
caus
acut
gastroenter
andor
bronchiol
sinc
bocaviru
may
associ
asymptomat
shed
etiolog
agent
bronchiol
determin
viral
load
may
help
distinguish
absenc
coronaviru
lead
us
specul
caus
benign
ill
lead
hospit
admiss
enteroviru
usual
associ
infect
summer
month
normal
associ
vri
limit
studi
includ
sampl
loss
collect
perform
pcr
use
residu
clinic
sampl
extend
studi
summer
month
potenti
decreas
detect
piv
ev
infect
includ
bronchiol
season
result
confirm
rsv
frequent
agent
also
highlight
potenti
signific
virus
adenoviru
hmpv
piv
children
hospit
bronchiol
given
presenc
viral
coinfect
rsv
bronchiol
import
recogn
potenti
limit
rapid
rsv
test
alon
consid
strategi
sequenti
test
respiratori
viru
littl
danger
certainli
miss
detect
case
market
rtpcr
kit
perform
test
rapidli
use
one
sampl
anoth
limit
includ
admit
children
chang
rate
detect
viru
howev
sever
case
one
need
investig
aap
state
virolog
test
use
patient
cohort
possibl
think
pcr
accur
method
higher
detect
rate
ifa
also
costeffect
enough
case
